Gadoxetic Acid-Enhanced MRI-Based Radiomic Models for Preoperative Risk Prediction and Prognostic Assessment of Proliferative Hepatocellular Carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.This study developed radiomics models and a nomogram to predict and stratify risk for proliferative hepatocellular carcinoma (HCC). The delta radiomics model demonstrated the best performance in predicting patient survival outcomes.
Area Of Science
- Radiology
- Oncology
- Medical Imaging
Background
- Proliferative hepatocellular carcinoma (HCC) presents significant clinical challenges due to its high invasiveness and poor prognosis.
- Accurate preoperative risk prediction and prognostic stratification are crucial for managing proliferative HCC.
Purpose Of The Study
- To investigate the preoperative risk prediction and prognostic value of different radiomics models and a nomogram for proliferative HCC.
- To assess the diagnostic efficacy and clinical utility of these predictive models.
Main Methods
- Radiomics features were extracted from T1-weighted imaging (T1WI) across multiple phases (arterial, hepatobiliary).
- Original and delta radiomics features were used to construct machine learning models.
- A nomogram was developed integrating the optimal radiomics model score with independent clinical risk factors (BCLC stage).
Main Results
- The developed nomogram demonstrated good predictive performance, with an AUC of 0.838 (training) and 0.801 (validation).
- BCLC stage and the combined radiomics score were identified as independent predictors of proliferative HCC.
- The delta radiomics (DR) model showed the best performance in independently predicting recurrence-free survival (RFS) and overall survival (OS), excelling in prognostic risk stratification.
Conclusions
- The nomogram effectively predicts proliferative HCC.
- Various radiomics models and the nomogram provide valuable prognostic stratification for patients with proliferative HCC.
- The delta radiomics model shows particular promise for survival prediction in this patient group.

